Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Overview

NASDAQ:INKT - US6036932019 - Common Stock

14.24 USD
-0.58 (-3.91%)
Last: 8/29/2025, 8:00:02 PM
14.67 USD
+0.43 (+3.02%)
After Hours: 8/29/2025, 8:00:02 PM

INKT Key Statistics, Chart & Performance

Key Statistics
52 Week High76
52 Week Low4.56
Market Cap64.36M
Shares4.52M
Float1.56M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.88
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/bmo
IPO10-15 2021-10-15
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


INKT short term performance overview.The bars show the price performance of INKT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

INKT long term performance overview.The bars show the price performance of INKT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 60

The current stock price of INKT is 14.24 USD. In the past month the price decreased by -3.26%. In the past year, price increased by 75.8%.

MINK THERAPEUTICS INC / INKT Daily stock chart

INKT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About INKT

Company Profile

INKT logo image MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Company Info

MINK THERAPEUTICS INC

149 Fifth Avenue, Suite 500

New York City NEW YORK US

Employees: 23

INKT Company Website

INKT Investor Relations

Phone: 12129948250

MINK THERAPEUTICS INC / INKT FAQ

What is the stock price of MINK THERAPEUTICS INC today?

The current stock price of INKT is 14.24 USD. The price decreased by -3.91% in the last trading session.


What is the ticker symbol for MINK THERAPEUTICS INC stock?

The exchange symbol of MINK THERAPEUTICS INC is INKT and it is listed on the Nasdaq exchange.


On which exchange is INKT stock listed?

INKT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MINK THERAPEUTICS INC stock?

9 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 179.35% is expected in the next year compared to the current price of 14.24. Check the MINK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MINK THERAPEUTICS INC worth?

MINK THERAPEUTICS INC (INKT) has a market capitalization of 64.36M USD. This makes INKT a Micro Cap stock.


How many employees does MINK THERAPEUTICS INC have?

MINK THERAPEUTICS INC (INKT) currently has 23 employees.


What are the support and resistance levels for MINK THERAPEUTICS INC (INKT) stock?

MINK THERAPEUTICS INC (INKT) has a support level at 14.23 and a resistance level at 15.99. Check the full technical report for a detailed analysis of INKT support and resistance levels.


Should I buy MINK THERAPEUTICS INC (INKT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MINK THERAPEUTICS INC (INKT) stock pay dividends?

INKT does not pay a dividend.


When does MINK THERAPEUTICS INC (INKT) report earnings?

MINK THERAPEUTICS INC (INKT) will report earnings on 2025-11-12, before the market open.


What is the Price/Earnings (PE) ratio of MINK THERAPEUTICS INC (INKT)?

MINK THERAPEUTICS INC (INKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.88).


What is the Short Interest ratio of MINK THERAPEUTICS INC (INKT) stock?

The outstanding short interest for MINK THERAPEUTICS INC (INKT) is 3.47% of its float. Check the ownership tab for more information on the INKT short interest.


INKT Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is one of the better performing stocks in the market, outperforming 96.14% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

INKT Financial Highlights

Over the last trailing twelve months INKT reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS increased by 41.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -453.8%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-51.43%
Sales Q2Q%N/A
EPS 1Y (TTM)41.22%
Revenue 1Y (TTM)N/A

INKT Forecast & Estimates

9 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 179.35% is expected in the next year compared to the current price of 14.24.


Analysts
Analysts77.78
Price Target39.78 (179.35%)
EPS Next Y43.59%
Revenue Next YearN/A

INKT Ownership

Ownership
Inst Owners1.58%
Ins Owners8.09%
Short Float %3.47%
Short Ratio0.03